Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis.

Songke Wu, Chengshi Wang, Shuyun Liu

Abstract read

In one paragraph

Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Integrating Tumour Biology into Surgical Decision-Making for Metastatic Colorectal Cancer: A Real-World Cohort Analysis Adapted for Clinical Colorectal Cancer.Cancers · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Songke WuDepartment of Oncology, Cangxi People's Hospital, Guangyuan, Sichuan 628400, P.R. China.

Chengshi WangDepartment of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

Shuyun LiuDepartment of General Surgery and NHC Key Laboratory of Transplant Engineering and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal first-line treatments for RAS wild-type metastatic colorectal cancer (mCRC) remain uncertain, despite the availability of numerous targeted therapies. Direct comparisons between all available regimens are limited, necessitating indirect evidence synthesis. A systematic review and network meta-analysis of randomized controlled trials (RCTs) comparing first-line treatments for RAS wild-type mCRC was conducted in the present study. MEDLINE/PubMed, Embase, Cochrane Central Register of Controlled Trials and Web of Science were searched from inception to September 2025. Primary outcomes included overall survival (OS) and progression-free survival (PFS), while secondary outcomes included objective response rate (ORR) and safety profiles. Random-effects network meta-analyses were performed and treatments were ranked using P-scores. In total, 15 RCTs involving 6,298 patients and seven primary treatment nodes were included. The network demonstrated high levels of consistency for OS (I

Indexed as

anti-EGFR therapybevacizumabfirst-line treatmentmetastatic colorectal cancernetwork meta-analysispersonalized medicineRAS wild-typeUDP glucuronosyltransferase family 1 member A1

Identifiers

PMID42305981

DOI10.3892/mco.2026.2960

PMCPMC13266398

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.